Based on the results of part 1 of the Phase III ESSENCE trial, the FDA on 15 August 2025 [38] and the EMA on 26 March 2026 [39] conditionally approved semaglutide 2.4 mg/week for the treatment of adults with non-cirrhotic MASH and moderate-to-advanced fibrosis
21: 1323 De Grandis D
instead, we rely on gut microbes to slowly ferment fibers like cellulose, hemicellulose, and -glucans in the large intestine.29 By starting that breakdown earlier in the digestive tract, supplemental fiber-targeting enzymes are designed to make very high-fiber meals feel more comfortable and, in theory, to improve access to trapped nutrients
December 2025: Ajanta Pharma inked a supply and marketing deal with Biocon, granting exclusive rights across 23 emerging markets and semi-exclusive rights in three more, strengthening Ajantas footprint in metabolic care
Second, it supports optimal cellular function, empowering your body to perform at its best